Patents Examined by Yong Pak
  • Patent number: 8759060
    Abstract: The present invention is directed to an arginine/lysine oxidoreductase modified with polyethylene glycol, a production method thereof, and methods of treating disorders responsive to a modification of amino acid levels reactive oxygen species and/or ammonium.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: June 24, 2014
    Inventors: Christian J. Hofmann, Michael Lindemann
  • Patent number: 8759066
    Abstract: Disclosed are compositions for activating thrombin precursors to thrombin. The compositions provided include polypeptide compositions wherein the pre-pro-sequence comprises a thrombin cleavage site. The compositions provided also include polynucleotides encoding said polypeptides and recombinant systems for expressing said polypeptides. This disclosure also relates to methods for producing said compositions, recovering said compositions, activating said compositions purifying said compositions and producing active thrombin molecules using the active form of said compositions.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: June 24, 2014
    Assignee: Zymogenetics, Inc.
    Inventors: Paul D. Bishop, Tracey A. Pownder, Paul O. Sheppard, Christopher J. Stenland
  • Patent number: 8753862
    Abstract: The present invention relates to novel expression cassettes and expression vectors, comprising three nucleic acid sequences for araA, araB and araD, each coding for a polypeptide of an L-arabinose metabolic pathway, in particular, a bacterial L-arabinose metabolic pathway. The invention particularly relates to expression cassettes and expression vectors, comprising codon-optimised nucleic acid sequences for araA, araB and araD. The invention further relates to host cells, in particular modified yeast strains containing the expression cassettes or expression vectors and expressing the polypeptides for the L-arabinose metabolic pathway, in particular, for the bacterial L-arabinose metabolic pathway. When using these modified host cells, arabinose is more effectively fermented by these cells, in particular into ethanol. The present invention is therefore relevant, inter alia, in connection with the production of biochemicals from biomass, such as bioethanol for example.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: June 17, 2014
    Assignee: Butalco GmbH
    Inventors: Eckhard Boles, Beate Wiedemann
  • Patent number: 8747840
    Abstract: Isolated glycyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: June 10, 2014
    Assignee: aTyr Pharma, Inc.
    Inventors: Leslie Ann Greene, Ryan Andrew Adams, Fei Hong, Ji Zhao, Eva Rebecka Stephanie Armour, Kristi Helen Piehl
  • Patent number: 8741616
    Abstract: Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily at the 2-positio to form S-2-octanol (40% ee). Another mutant, 1-12G, hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-2-alcohols (40-55% ee). These biocatalysts are highly active for alkane substrates and support thousands of product turnovers. These regio- and enantio-selectivities are retained in whole-cell biotransformations with E. coli, where the engineered P450s can be expressed at high levels and the expensive cofactor is supplied endogenously.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: June 3, 2014
    Assignee: California Institute of Technology
    Inventors: Frances H. Arnold, Matthew W. Peters, Peter Meinhold
  • Patent number: 8741624
    Abstract: Recombinant processes are provided whereby additional genes are introduced into E. coli which have been genetically engineered to produce PHA so that the improved strains produce PHA homopolymers and copolymers directly from diols. In preferred embodiments, PHAs containing 4-hydroxybutyrate monomers are produced directly from 1,4-butanediol; PHAs containing 5-hydroxyvalerate are produced from 1,5-pentanediol; PHAs containing 6-hydroxyhexanoate (6HH) are produced from 1,6-hexanediol; PHAs containing 3-hydroxypropionate are produced from 1,3-propanediol; PHAs containing 2-hydroxypropionate (lactate) are produced from 1,2-propanediol (propylene glycol); PHAs containing 2-hydroxyethanoate (glycolate) are produced from 1,2-ethanediol (ethylene glycol). Genes encoding these same enzyme activities can be introduced or their expression amplified in wild type PHA producers to improve the production of PHA homopolymers and copolymers directly from diol and other alcohol feedstocks.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: June 3, 2014
    Assignee: Metabolix, Inc.
    Inventors: Frank A. Skraly, Martha Sholl
  • Patent number: 8735122
    Abstract: Recombinant purified DnaK—having a ATPase activity without the addition of an other chaperone protein—essentially free of T-cell stimulating impurities.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: May 27, 2014
    Assignee: Biotech Tools S.A.
    Inventors: Frederic Henot, Thierry Legon, Sabine Pirotton, Gael Placier
  • Patent number: 8728791
    Abstract: The present invention provides a microorganism which possesses the formate dehydrogenase gene and hydrogenase gene and contains an exogenous transcription activator gene for formate hydrogen lyase system, characterized in that said microorganism shows the transcription activator for formate hydrogen lyase system highly expressed therein and shows an improved function to generate hydrogen from formic acid, and a process for producing hydrogen using the microorganism. Utilization of the microorganism of the present invention enables the hydrogen production from an organic substrate to be accomplished on a practical, commercial scale. The hydrogen to be produced by the present invention, which is free of carbon monoxide being causative to poisoning of the electrode catalyst for fuel cells, is useful as a fuel for fuel cells.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: May 20, 2014
    Assignees: Research Institute of Innovative Technology for the Earth, Sharp Corporation
    Inventors: Hideaki Yukawa, Masayuki Inui, Akihito Yoshida, Naoto Torata
  • Patent number: 8722371
    Abstract: Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: May 13, 2014
    Assignee: California Institute of Technology
    Inventors: Edgardo T. Farinas, Frances H. Arnold, Ulrich Schwaneberg, Anton Blieder
  • Patent number: 8716208
    Abstract: A solid particulate laundry detergent composition including: (a) polyethylene glycol polymer including a polyethylene glycol backbone and polyvinyl acetate side chains, wherein the average molecular weight of the polyethylene glycol backbone is in the range of from 4,000 Da to 8,000 Da, wherein the molecular weight ratio of the polyethylene glycol backbone to the polyvinyl acetate side chains is in the range of from 1:1.2 to 1:2, and wherein the average number of graft sites per ethylene oxide units is in the range of from 0.2 to 0.4; (b) amylase with greater than 90% identity to the AA560 alpha amylase endogenous to Bacillus sp. DSM 12649 and including: (i) mutations at one or more of positions 9, 149, 182, 186, 202, 257, 295, 299, 323, 339 and 345; and (ii) mutations at four or more of positions 118, 183, 184, 195, 320 and 458; and (c) laundry detergent ingredients.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: May 6, 2014
    Assignee: The Procter & Gamble Company
    Inventors: Michelle Meek, Philip Frank Souter, Neil Joseph Lant, Alan Thomas Brooker, Nigel Patrick Somerville Roberts
  • Patent number: 8715993
    Abstract: A thermostable glycosidase enzymes derived from various Thermococcus, Staphylothermus and Pyrococcus organisms is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry, pharmaceutical industry and in the textile industry, detergent industry and in the baking industry.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: May 6, 2014
    Assignee: BP Corporation North America Inc.
    Inventors: Edward J. Bylina, Ronald V. Swanson, Eric J. Mathur, David E. Lam
  • Patent number: 8709772
    Abstract: This invention relates generally to enzymes, polynucleotides encoding the enzymes, the use of such polynucleotides and polypeptides and more specifically to enzymes having transferase activity, e.g., transaminase activity, e.g., d-amino-acid transferase activity, and/or oxidoreductase activity, e.g., dehydrogenase activity, e.g., damino-acid dehydrogenase activity, and/or catalyze the transfer of a chemical group, catalyze transamination, catalyze the reaction: D-alanine+2-oxoglutarate<=>pyruvate+D-glutamate, and/or catalyze an oxidation-reduction reaction, catalyze the removal of hydrogen atoms, and/or catalyze the reaction: D-amino acid+H2O+acceptor<=>a 2-oxo acid+NH3+reduced acceptor.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: April 29, 2014
    Assignee: Verenium Corporation
    Inventors: David P. Weiner, Peter Luginbuhl, Analia Bueno, Joslin Cuenca, Erin Marasco
  • Patent number: 8703471
    Abstract: A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. Escherichia coli) into which is introduced a genetic information encoding for a metabolic apparatus capable of carrying out the requested N-glycosylation of the target protein. Said prokaryotic organism also contains the genetic information required for the expression of one or more recombinant target proteins. The metabolic apparatus preferably comprises specific glycosyltransferases for the assembly of the oligosaccharide on a lipid carrier and an OTase that covalently links this oligosaccharide to specific residues of the desired protein.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: April 22, 2014
    Assignee: ETH Zürich
    Inventors: Markus Aebi, Michael Wacker
  • Patent number: 8703449
    Abstract: Genetically engineered organisms for production of PHA copolymers containing 2-hydroxyacid monomers and the methods of making and using thereof have been developed. The copolymers containing 2-hydroxyacid monomers can be synthesized via biosynthesis by the action of a PHA polymerase in a living cell. By changing the genetic background of the cells, one can control specific metabolic pathways allowing control of the level of glycolic acid co-monomer in the PHA polymer.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: April 22, 2014
    Assignee: Metabolix, Inc.
    Inventors: David P. Martin, Frank A. Skraly
  • Patent number: 8703462
    Abstract: An enzyme preparation is described that includes a non-specific nuclease and a T7 Endo I mutant in a unit ratio of less than 1:200. This enzyme preparation may be used to generate double-stranded DNA fragments of a size suitable for DNA sequencing. The ends of the fragments can be readily modified as necessary to ligate adaptors or individual nucleotides to one strand of the double-stranded DNA fragments.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: April 22, 2014
    Assignee: New England Biolabs, Inc.
    Inventors: Pei-Chung Hsieh, Chudi Guan
  • Patent number: 8685664
    Abstract: Novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: April 1, 2014
    Assignee: Probiodrug AG
    Inventors: Hans-Ulrich Demuth, Torsten Hoffmann, Andre Johannes Niestroj, Stephan Schilling, Ulrich Heiser
  • Patent number: 8679818
    Abstract: The present invention provides a novel ?-glucosidase nucleic acid sequence, designated bgl7, and the corresponding BGL7 amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding BGL7, recombinant BGL7 proteins and methods for producing the same.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: March 25, 2014
    Assignee: Danisco US Inc.
    Inventors: Nigel Dunn-Coleman, Michael Ward
  • Patent number: 8673614
    Abstract: A microbial composition for concurrent dechlorination of a mixture of chlorinated ethanes and chlorinated ethenes includes a isolated consortium of bioremediative microorganisms comprising strains of microorganism comprising Clostridium, Acetobacterium, Dehalobacter, Bacteroides, and Proteobacteria. The composition may also include Methanomicrobia.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: March 18, 2014
    Assignee: The United States of Amerivca as represeted by the Secretary of the Army
    Inventors: Michelle M. Lorah, Elizabeth J. Jones, Mary A. Voytek
  • Patent number: 8669088
    Abstract: An object of the present invention is to provide enzymes associated with equol synthesis, genes coding such enzymes, and a process for producing equol and its intermediates using the enzymes and genes. The present invention provides a dihydrodaidzein synthesizing enzyme, tetrahydrodaidzein synthesizing enzyme, equol synthesizing enzyme, and genes coding these enzymes. The present invention also provides a process for synthesizing dihydrodaidzein, tetrahydrodaidzein, and/or equol using these enzymes.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: March 11, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Yoshikazu Shimada, Setsuko Yasuda, Masayuki Takahashi, Takashi Hayashi, Norihiro Miyazawa, Yasuhiro Abiru, Tadaaki Ohtani, Ikutaro Sato
  • Patent number: 8663629
    Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: March 4, 2014
    Assignee: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner